{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,5]],"date-time":"2026-07-05T00:15:18Z","timestamp":1783210518576,"version":"3.54.6"},"reference-count":32,"publisher":"SAGE Publications","issue":"2_suppl","license":[{"start":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Parkinson\u2019s Disease"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:p>Parkinson's disease (PD) is the second most frequent neurodegenerative disorder, and its prevalence has doubled in the past 25 years. New formulations of levodopa have recently been marketed that improved the ability to treat PD, but in the European Union, no new active substance for PD has been marketed since 2015, whilst two new agents have been marketed elsewhere. In spite of being the most treatable neurodegenerative disorder, several unmet medical needs still exists in PD, and efforts both from researchers, drug developers and regulators are needed to facilitate further developments in the field. There are several reasons that may account for the lack of new treatments for PD. Regulatory agencies provide scientific advice and have developed several programs to foster drug development. This manuscript discusses the main obstacles identified in the development process, the present status of approvals in European Union and the United States, and the presently available mechanisms to optimize drug development and marketing.<\/jats:p>","DOI":"10.1177\/1877718x251360584","type":"journal-article","created":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T06:31:46Z","timestamp":1754548306000},"page":"47-54","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["Can regulators have a role in facilitating the development of new medicines for Parkinson's disease?"],"prefix":"10.1177","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3158-2106","authenticated-orcid":false,"given":"M\u00e1rio Miguel","family":"Rosa","sequence":"first","affiliation":[{"name":"Lisbon Medical School, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal"},{"name":"Scientific Advice Working Party, EMA, Amsterdam, The Netherlands"},{"name":"Central Nervous System Working Party, EMA, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8882-9769","authenticated-orcid":false,"given":"Ewa","family":"Balkowiec-Iskra","sequence":"additional","affiliation":[{"name":"Scientific Advice Working Party, EMA, Amsterdam, The Netherlands"},{"name":"Central Nervous System Working Party, EMA, Amsterdam, The Netherlands"},{"name":"Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Warsaw, Poland"},{"name":"The Office for Registration of Medicinal Products, Medical Devices and Biocidal Products, Warsaw, Poland"},{"name":"Committee for Medicinal Products for Human Use, European Medicines Agency, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,8,6]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01478-2"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.3390\/biom11040612"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-018-0058-0"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30499-X"},{"key":"e_1_3_3_6_2","volume-title":"Global health estimates 2020: Disease burden by cause, age, sex by country and by region, 2000\u2013 2019","year":"2020","unstructured":"Global health estimates 2020: Disease burden by cause, age, sex by country and by region, 2000\u2013 2019. Geneva: World Health Organization, 2020."},{"key":"e_1_3_3_7_2","unstructured":"The Pharmaceutical Industry in Figures. EFPIA. https:\/\/efpia.eu\/media (2024 accessed 17 November 2024)."},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3079"},{"key":"e_1_3_3_9_2","unstructured":"Nouryant. European Medicines Agency. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/nouryant (accessed 12 November 2024)."},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.8940-21"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2017.09.018"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2015.05.014"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-019-01014-4"},{"key":"e_1_3_3_14_2","unstructured":"carbidopa\/levodopa: List of nationally authorised medicinal products - PSUSA\/00000548\/201910. https:\/\/www.ema.europa.eu\/en\/documents\/psusa\/carbidopa-levodopa-list-nationally-authorised-medicinal-products-psusa00000548201910_en.pdf (accessed 17 November 2024)."},{"key":"e_1_3_3_15_2","unstructured":"EPAR Inbrija INN-levodopa. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/inbrija (accessed 4 November 2024)."},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01307-x"},{"key":"e_1_3_3_17_2","unstructured":"FDA approves first drug to treat hallucinations and delusions associated with Parkinson\u2019s disease. https:\/\/parkinsonsnewstoday.com\/news\/fda-approves-acadia-pharmaceuticals-nuplazid-pimavanserin-the-first-drug-approved-for-the-treatment-of-hallucinations-and-delusions-associated-with-parkinsons-disease-p\/ (accessed 4 November 2024)."},{"key":"e_1_3_3_18_2","unstructured":"Academia | European Medicines Agency. https:\/\/www.ema.europa.eu\/en\/partners-networks\/academia (accessed 15 November 2024)."},{"key":"e_1_3_3_19_2","unstructured":"Scientific advice and protocol assistance. https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/research-development\/scientific-advice-protocol-assistance (accessed 12 November 2024)."},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00264-7"},{"key":"e_1_3_3_21_2","unstructured":"PRIME: priority medicines. https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/research-development\/prime-priority-medicines (accessed 12 November 2024)"},{"key":"e_1_3_3_22_2","unstructured":"Qualification of novel methodologies for drug development: guidance to applicants. https:\/\/www.ema.europa.eu\/en\/documents\/regulatory-procedural-guideline\/qualification-novel-methodologies-drug-development-guidance-applicants_en.pdf (accessed 12 November 2024)."},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1038\/d41573-020-00205-x"},{"key":"e_1_3_3_24_2","unstructured":"Guideline on clinical investigation of medicinal products in the treatment of Parkinson\u2019s disease. https:\/\/www.ema.europa.eu\/en\/clinical-investigation-medicinal-products-treatment-parkinsons-disease-scientific-guideline (accessed 12 November 2024)."},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1159\/000117399"},{"key":"e_1_3_3_26_2","unstructured":"ICH E9 statistical principles for clinical trials - Scientific guideline. https:\/\/www.ema.europa.eu\/en\/ich-e9-statistical-principles-clinical-trials-scientific-guideline (accessed 12 November 2024)."},{"key":"e_1_3_3_27_2","volume-title":"BEST (Biomarkers, EndpointS, and other Tools) Resource [Internet]","author":"FDA-NIH Biomarker Working Group","year":"2016","unstructured":"FDA-NIH Biomarker Working Group. BEST (Biomarkers, EndpointS, and other Tools) Resource [Internet]. Silver Spring (MD): Food and Drug Administration (US), 2016. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK326791\/ Co-published by National Institutes of Health (US), Bethesda (MD)."},{"key":"e_1_3_3_28_2","unstructured":"Revisions of the McDonald diagnostic Criteria for MS. https:\/\/ectrims.eu\/mcdonald-diagnostic-criteria (accessed 4 November 2024)"},{"key":"e_1_3_3_29_2","unstructured":"Guidance on outcomes for joint clinical assessments. https:\/\/health.ec.europa.eu\/document\/download\/a70a62c7-325c-401e-ba42-66174b656ab8_en?filename=hta_outcomes_jca_guidance_en.pdf (accessed 12 November 2024)"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2024.09.003"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-024-00716-z"},{"key":"e_1_3_3_32_2","unstructured":"MDS COA Critiques and Recommendations. https:\/\/www.movementdisorders.org\/MDS\/MDS-Rating-Scales\/Rating-Scales-Critiques-and-Recommendations.htm#Parkinson_s_Disease_Rating_Scales (accessed 12 November 2024)."},{"key":"e_1_3_3_33_2","unstructured":"Revised transparency rules for the EU Clinical Trials Information System (CTIS). European Medicines Agency; 2023 https:\/\/www.ema.europa.eu\/en\/documents\/other\/revised-ctis-transparency-rules_en.pdf (accessed 12 November 2024)."}],"container-title":["Journal of Parkinson\u2019s Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1877718X251360584","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1877718X251360584","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1877718X251360584","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T23:21:18Z","timestamp":1783207278000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1877718X251360584"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,6]]},"references-count":32,"journal-issue":{"issue":"2_suppl","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.1177\/1877718X251360584"],"URL":"https:\/\/doi.org\/10.1177\/1877718x251360584","relation":{},"ISSN":["1877-7171","1877-718X"],"issn-type":[{"value":"1877-7171","type":"print"},{"value":"1877-718X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,6]]}}}